Gain Therapeutics Inc. (GANX)
Gain Therapeutics Inc. (GANX) Stock Price, Analysis & Data
| Bid | 1.28 |
| Market Cap | 92.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.24M |
| Beta | 0.20 |
| EPS (ttm) | -0.59 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.8 |
| P/B (ttm) | 6.56 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.27 |
| Volume | 1,327,502 |
| Avg. Volume (20D) | 896,577 |
| Open | 2.15 |
| Previous Close | 2.12 |
| Day's Range | 2.13 - 2.37 |
| 52-Week Range | 1.51 - 4.34 |
| Analyst | n/a |
| Price Target | 8 (268.66%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GANX
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead...
Financial Performance
In 2025, Gain Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -20.16M, a decrease of -1.23%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for GANX stock is "null". The 12-month stock price forecast is 8, which is upside of 268.66% from the latest price.
Stock Forecasts
